Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cancer metabolism refers to the alterations in cellular metabolism pathways that are evident in cancer cells compared with most normal tissue cells. Metabolic alterations in cancer cells are numerous and include aerobic glycolysis, reduced oxidative phosphorylation and the increased generation of biosynthetic intermediates needed for cell growth and proliferation.
Reprogrammed metabolism has been long recognized as a driver of kidney cancer progression, prompting efforts to develop metabolic targeted therapies against this disease. Evidence offers further clarity on the metabolic phenotypes associated with aggressive disease, expanding the potential target space for attacking these tumours at their metabolic roots.
Lim et al. show that ASS1, silenced in many cancer types, is a metabolic checkpoint that, following DNA damage, halts cell cycle progression by restricting nucleotide synthesis and p53-related gene transcription.
Reprogrammed metabolism has been long recognized as a driver of kidney cancer progression, prompting efforts to develop metabolic targeted therapies against this disease. Evidence offers further clarity on the metabolic phenotypes associated with aggressive disease, expanding the potential target space for attacking these tumours at their metabolic roots.
Monteran et al. identified key interactions between granulocytes and T cells that promote an immunosuppressive bone microenvironment, enabling breast cancer metastasis.
Tumor fibrosis is known to suppress anti-tumor immunity. A new study now highlights the role of tumor-associated macrophages in coordinating fibrosis-mediated metabolic changes in tumors, restricting cytotoxic T cell responses and contributing to tumor growth.
For many years, PSA has been the most commonly used biomarker for prostate cancer screening and diagnosis. Although serum PSA measurement is highly sensitive, this biomarker has several limitations. Citrate, a molecule closely linked to the unique metabolism of prostate cancer, has the potential to be used as a complementary biomarker alongside PSA.